Drug Trial Radar · NCT06012240
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,500
Planned (sponsor's estimate)
Start
Oct 11, 2023
Primary completion
Apr 2030
Study completion Apr 2030
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Aug 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 63 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and face, but hair loss can happen on any part of the body. The purpose of this study is to assess how safe, effective, and tolerable upadacitinib is in adolescent and adult participants with severe AA. Upadacitinib is an approved drug being investigated for the treatment of AA. In Study 1 and Study 2 and Study 4 Period A, participants are placed in 1 of 3 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 5 chance that participants will be assigned to placebo. In Study 1 and Study 2 and Study 4 Period B, participants originally randomized to upadacitinib dose group in Period A will continue their same treatment in Period B. Participants originally randomized to Placebo in Period A will either remain on placebo in Period B, or be randomized in 1 of 2 groups, based off of their Severity of Alopecia Tool (SALT) score. Participants who complete Study 1, Study 2 or Study 4, can join Study 3 and may be re-randomized to receive 1 of 2 doses of upadacitinib for up to 108 weeks. Around 1500 participants with severe AA will be enrolled in the study at approximately 280 sites worldwide. Participants will receive oral tablets of either upadacitinib or placebo once daily for up to 160 weeks with the potential of being re-randomized into a different treatment group at Weeks 24 and 52. Participants will be followed up for up to 30 days after last study drug dose. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Alopecia Areata
Interventions
UpadacitinibDrug
Oral Tablets
PlaceboDrug
Oral Tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with the Achievement of Severity of Alopecia Tool (SALT) Score <= 20Time frame: Week 24
- Number of Participants with Adverse Events (AEs)Time frame: Up to approximately 164 weeks
Locations
272 sites in 28 countries. Site status is shown where the registry gives one.
Total Skin and Beauty Dermatology Center /ID# 259539
Birmingham, Alabama · Active not recruiting
Duplicate_Advanced Research Associates - Glendale /ID# 259108
Glendale, Arizona · Completed
Southwest Skin Specialists /ID# 258234
Phoenix, Arizona · Completed
Alliance Dermatology and Mohs Center /ID# 258111
Phoenix, Arizona · Active not recruiting
Johnson Dermatology Clinic /ID# 259103
Fort Smith, Arkansas · Active not recruiting
Duplicate_JOSEPH RAOOF MD,INC /ID# 258031
Encino, California · Completed
First Oc Dermatology /ID# 259220
Fountain Valley, California · Recruiting
University of California Irvine /ID# 259096
Irvine, California · Active not recruiting
Dermatology Research Associates /ID# 258033
Los Angeles, California · Recruiting
Stanford University School of Medicine - Redwood City /ID# 259542
Redwood City, California · Completed
Integrative Skin Science and Research /ID# 258114
Sacramento, California · Recruiting
University of California Davis Health /ID# 258112
Sacramento, California · Recruiting
Clinical Trials Research Institute /ID# 258021
Thousand Oaks, California · Recruiting
Skin Care Research Boca Raton /ID# 258012
Boca Raton, Florida · Recruiting
Apex Clinical Trials /ID# 259205
Brandon, Florida · Active not recruiting
Florida Academic Dermatology Center /ID# 259353
Coral Gables, Florida · Active not recruiting
Skin Research Institute LLC /ID# 259207
Coral Gables, Florida · Completed
Revival Research /ID# 259213
Doral, Florida · Completed
Skin Care Research - Hollywood /ID# 259210
Hollywood, Florida · Recruiting
GSI Clinical Research, LLC /ID# 259352
Margate, Florida · Recruiting
Life Clinical Trials - N State Rd - Margate /ID# 259358
Margate, Florida · Active not recruiting
Lenus Research and Medical Group /ID# 259356
Miami, Florida · Recruiting
International Clinical Research - Sanford /ID# 259547
Sanford, Florida · Completed
FWD Clinical Research /ID# 266687
Tamarac, Florida · Completed
Advanced Clinical Research Institute - Tampa /ID# 259204
Tampa, Florida · Recruiting
Avita Clinical Research /ID# 258011
Tampa, Florida · Completed
Cleaver Medical Group Dermatology /ID# 259801
Dawsonville, Georgia · Active not recruiting
Marietta Dermatology /ID# 259818
Marietta, Georgia · Active not recruiting
Northwestern Medicine - Northwestern Memorial Hospital /ID# 259555
Chicago, Illinois · Completed
NorthShore University HealthSystem - Skokie /ID# 266684
Skokie, Illinois · Active not recruiting
Indiana University Health University Hospital /ID# 259827
Indianapolis, Indiana · Recruiting
U.S. Dermatology Partners Leawood /ID# 259203
Leawood, Kansas · Completed
Tulane University School of Medicine /ID# 259799
New Orleans, Louisiana · Recruiting
Raven Clinical Research /ID# 268453
Marriottsville, Maryland · Completed
MetroBoston Clinical Partners /ID# 259559
Boston, Massachusetts · Active not recruiting
Lahey Hospital and Medical Center /ID# 260484
Burlington, Massachusetts · Completed
Great Lakes Research Group - Bay City /ID# 259100
Bay City, Michigan · Completed
Derm Institute of West Michigan /ID# 259546
Caledonia, Michigan · Recruiting
Hamzavi Dermatology - Canton /ID# 260115
Canton, Michigan · Completed
Clarkston Dermatology /ID# 258018
Clarkston, Michigan · Recruiting
Showing 40 of 272 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.